Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
MSFT$554.19+35.02(+6.72%)UK Stocks-Factors to watch on November 512:52:05 AM ETMSFT$554.19+35.02(+6.72%)UPDATE 1-Microsoft rejects multibillion-dollar AI deal with UK's Nscale, FT reports12:44:24 AM ETBRK.A$869,300.76+32,855.63(+3.93%)Berkshire Hathaway: The Easy Re-Rating Is Gone12:39:39 AM ETMSFT$554.19+35.02(+6.72%)Microsoft rejects multibillion-dollar AI deal with UK's Nscale, FT reports12:11:41 AM ETMSFT$554.19+35.02(+6.72%)BRIEF-Microsoft Rejects Multibillion-Dollar AI Deal With UK's Nscale - FT12:11:33 AM ETMSFT$554.19+35.02(+6.72%)Microsoft rejects multibillion-dollar AI deal with UK's Nscale, FT reports12:09:40 AM ETTM$205.56+6.45(+3.34%)Toyota profit surges 34%, first rise in six quarters12:02:07 AM ETC$124.58+1.89(+1.54%)UPDATE 1-Oil falls for a fourth day on expectations for lower risk of Iran war escalation11:59:47 PM ETQCOM$160.25+8.76(+5.33%)SpaceX Makes Its Biggest Move Yet Against Telecom Giants With Qualcomm 5G Deal: Elon Musk Hails QCOM's Technology, Calls It 'Excellent'11:59:02 PM ETMCD$278.93+17.15(+6.52%)McDonald's: 3 Key Takeaways for Long-Term Investors11:46:01 PM ETQCOM$160.25+8.76(+5.33%)SpaceX Just Picked Qualcomm for Its Own 5G Network. I Still See the Stock as a Hold.11:41:01 PM ETIONQ$29.52-0.48(-1.60%)IonQ vs. SoundHound AI: Which Technology Stock Is a Better Buy for 2027?11:30:01 PM ETQCOM$160.25+8.76(+5.33%)Qualcomm Q4 Earnings Call Highlights11:27:00 PM ETAMD$485.27+4.95(+1.02%)AMD Stock Jumped After Its Report. I'd Wait for a Lower Price to Buy.11:17:01 PM ETGOOG$288.55+9.01(+3.24%)Google expands voluntary buyouts to 5 countries as AI spending fuels cost cuts11:16:50 PM ETSHOP$153.05+10.32(+7.23%)Shopify: 3 Key Takeaways for Long-Term Investors10:59:40 PM ETMCD$278.93+17.15(+6.52%)Why McDonald's Stock Popped Today10:45:31 PM ETMETA$630.20+8.87(+1.43%)Meta President Says Midterm Results Will Make Building Data Centers Harder10:11:00 PM ETPANW$348.32-2.07(-0.59%)BRIEF-Palo Alto Networks In Talks To Pay $500 Million For AI Security Startup Clutch Security - The Information9:57:31 PM ETMSFT$554.19+35.02(+6.72%)US STOCKS-Wall Street ends higher after Democrats win Congress; data center stocks tumble9:41:58 PM ETASML$1,479.73-72.05(-4.64%)ASML vs. Marvell Technology: Which Artificial Intelligence Stock Is a Better Buy Going into 2027?9:33:56 PM ETABT$115.40+6.10(+5.58%)DIARY-India economic, corporate events on November 59:00:32 PM ETNVO$41.87+1.67(+4.15%)Novo Nordisk: 3 Key Takeaways for Long-Term Investors8:55:55 PM ETAAPL$350.78+17.87(+5.39%)Apple is reportedly cutting budgets for its internal AI usage8:26:22 PM ET

IPHA · NASDAQ

Innate Pharma S.A.

$1.42 +0.09 (+7.14%)

Company overview

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials for refractory Sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trials to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinical trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase I clin…

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$153M
Employees
181
Headquarters
Marseille
Website
innate-pharma.com
CEO
Jonathan E. Dickinson
Listed
October 17, 2019
P/E
-1.22
Dividend yield
0.00%

Company financials

Revenue
$15.4M
Gross profit
$15.4M
Operating income
-$105M
EBITDA
-$103M
Net income
-$98.4M
EPS
-$1.16
Total assets
$62.7M
Total debt
$22.6M
Gross margin
100.00%
Net margin
-638.90%
Earnings yield
-81.69%

Price chart

1.261.642.022.392.77
IPHA 1D NASDAQ O1.40H1.43L1.38C1.43+0.09 (+7.14%)Vol9.50K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
IPHAInnate Pharma S.A. Press release Innate Pharma Reports Third Quarter 2026 Business and Financial Update Business Wire
IPHAInnate Pharma S.A. Stock news Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 GuruFocus
IPHAInnate Pharma S.A. Press release Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 Business Wire
IPHAInnate Pharma S.A. Press release Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference Business Wire
IPHAInnate Pharma S.A. Stock news Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update Business Wire
IPHAInnate Pharma S.A. Stock news Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a Turnaround Zacks Investment Research
IPHAInnate Pharma S.A. Stock news Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA) Zacks Investment Research
IPHAInnate Pharma S.A. Stock news Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know Zacks Investment Research
IPHAInnate Pharma S.A. Stock news Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript Seeking Alpha
IPHAInnate Pharma S.A. Stock news Innate Pharma Q2 Earnings Call Highlights MarketBeat
IPHAInnate Pharma S.A. Press release Innate Pharma Reports First Half 2026 Business Update and Financial Results Business Wire
IPHAInnate Pharma S.A. Press release Sobi and Innate announce partnership is now effective following completion of closing conditions PR Newswire
IPHAInnate Pharma S.A. Press release Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions Business Wire
IPHAInnate Pharma S.A. Press release Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update Business Wire
IPHAInnate Pharma S.A. Press release Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference Business Wire
IPHAInnate Pharma S.A. Stock news Innate Pharma Secures €30M, Extends Cash Runway Into 2028 MarketBeat
IPHAInnate Pharma S.A. Stock news Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript Seeking Alpha
IPHAInnate Pharma S.A. Press release Innate Pharma Announces Conference Call and Webcast Business Wire
IPHAInnate Pharma S.A. Stock news Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy Benzinga
IPHAInnate Pharma S.A. Press release Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma PRNewsWire
See more
FAQ

Questions about Innate Pharma S.A.

What does Innate Pharma S.A. do?
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials for refractory Sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trials to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinical trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase I clin…
What is IPHA's market cap?
Innate Pharma S.A. (IPHA) is a listed stock with a live quote. The latest market cap on this page is $153M.
Where is Innate Pharma S.A. headquartered?
Innate Pharma S.A. is headquartered in Marseille.
How do I get IPHA news from the API?
Call GET /v1/news?tickers=IPHA. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does IPHA news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for IPHA, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the IPHA price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs